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• Compression injury to the auditory nerve causes auditory spiral ganglion cell death 2 
and cochlear cell death. Subsequently, reactive astrocytes project numerous processes 3 
into the peripheral portion of the nerve (the astrocyte outgrowth). 4 
• Donor cells transplanted on the surface of the astrocyte outgrowth can autonomously 5 
enter the nerve, migrate, and integrate into the host leading to functional restoration. 6 
In contrast, when donor cells are injected into the nerve, they die.  7 
• Important structural and biochemical cues for axon regeneration embedded in the host 8 
can be harnessed by donor cells only when they are transplanted on the surface of the 9 
host, without disturbing astrogliosis/astrocyte scar.  10 
• We hypothesize that surface transplantation may be applied not only for motor neuron 11 
diseases but also for Alzheimer’s disease and Parkinson’s disease in which the lesions 12 
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Abstract 19 
Cell transplantation is ambitious but arguably realistic for repair of the nervous system. 20 
Cell delivery is a major challenge for clinical translation, especially given the apparently 21 
inhibitory astrogliotic environment in degenerated tissue. However, astrogliotic tissue 22 
also contains endogenous structural and biochemical cues that can be harnessed for 23 
functional repair. Minimizing damage to these cues during cell delivery could thus be 24 




astrocyte scar model, in which cells delivered onto the surface of the damaged nerve were 1 
more successfully integrated in the host than those injected into the tissue. We consider 2 
the application of this less invasive approach for nerve injury and its potential application 3 
to some neurodegenerative disorders.  4 
 5 
Cell transplantation and the astrocyte scar 6 
Replacement of lost neurons by cell transplantation has long been investigated as a possible 7 
treatment for spinal cord injury (SCI), and more recently also for neurodegenerative disorders 8 
(NDDs), including Parkinson’s disease (PD) (see Glossary), amyotrophic lateral sclerosis 9 
(ALS), Huntington’s disease (HD), multiple sclerosis (MS), temporal lobe epilepsy (TLE) 10 
and Alzheimer’s disease (AD) [1-7]. There is recent, encouraging evidence for successful 11 
integration of transplanted, exogenous grafts into host tissue [1-4] and in some cases it is 12 
associated with evidence for measurable improvement of patients’ signs and symptoms [5, 6]. 13 
Nevertheless, there are numerous hurdles to overcome for full clinical application, not least 14 
because astrogliosis, especially the astrocyte scar (the glial scar), is believed to generate 15 
mechanical and molecular barriers against regenerating axons [8, 9].  16 
  In this article we discuss a new and more positive view of the astrocyte scar and argue that 17 
its surface can play a pivotal role in the functional integration of donor cells. This is based on 18 
our experiments with an auditory astrocyte scar model (Box 1) in which donor cells (Box 2) 19 
placed on the surface of the nerve can enter the host tissue autonomously, migrate and 20 
differentiate to establish synaptic connections with peripheral and central targets and to restore 21 
measurable recovery of auditory function [10] (Figure 1) (Key Figure). We speculate that 22 
surface transplantation could be an effective way of exploiting the astrocyte scar in other kinds 23 





Intraparenchymal injection versus surface transplantation 1 
The most reliable method of cell transplantation has intuitively been believed to be direct 2 
injection of cells into the host nervous tissue, although there is little comparative work 3 
examining efficacy of different delivery strategies [11, 12]. In contexts where an astrocytic scar 4 
is involved, it would be a major advantage, we believe, if one could overcome the inhibition of 5 
the astrocyte scar using a less invasive approach that causes minimal destruction of healthy 6 
nerve tissue and supports maximal functional integration of donor cells. In this article we revisit 7 
critical aspects of intraparenchymal injection in the light of an alternative approach based upon 8 
surface transplantation. 9 
 10 
Mechanical damage to nervous tissue during intraparenchymal injection. 11 
A study by Wiesmann et al. demonstrated that even a small volume of Ringer’s solution 12 
intraneurally injected into pig brachial plexus nerves can induce local inflammation and myelin 13 
damage within the nerve [13]. In another experimental study in which human adipose-derived 14 
stem cells (hASCs) were epineurally or intraneurally injected into injured sciatic nerves of rats, 15 
improvement in mechanical allodynia was higher, and the results of the paw withdrawal test 16 
were better in the former compared to the latter group [11]. The authors concluded that 17 
intraneural injection is invasive and negates the beneﬁcial effect of hASCs. Also in the CNS, it 18 
is very likely that devices used for intraparenchymal injection, such as a syringe needle, 19 
mechanically injure CNS tissue. By itself, this can cause trauma that leads to activation of 20 
immuno-inﬂammatory cells and astrocytes [14-16]. Infusion pressure during cell or viral vector 21 
injection and the resulting cell or vector mass may damage residual functional neurons and their 22 
associated vascular networks [11] (see below), which can also reactivate astrocyte scar 23 
formation. Cells and viral vectors that cross the physiological border may cause unexpected and 24 




neuronal networks. In a study of ALS patients, donor cells were injected into up to 20 locations 1 
in the spinal cord via a needle penetrating the dorsal surface to reach the ventral horn. Serious 2 
complications, such as bilateral lower leg weakness and continued central pain syndrome were 3 
observed in some cases [17]. The outcome might have been more favorable with a less invasive 4 
method.  5 
 6 
Adaptation of donor cells to the host environment?  7 
Donor cells delivered intraparenchymally are placed abruptly into an alien, pathological host 8 
environment [7, 12] and are not supported by an immediate blood supply [15], leading to large 9 
scale donor cell death [18]. By contrast, in surface transplantation, donor cells are placed in 10 
cerebrospinal fluid (CSF) – known to be a major nourishing source for the central nervous 11 
system (CNS) [19] – before they establish a link to the blood supply. Somewhat surprisingly, 12 
pro-regenerative molecules, including brain-derived neurotrophic factor (BDNF) and insulin-13 
like growth factor 2 (IGF-2), are produced in the choroid plexus in the ventricle and released 14 
into the CSF. Thus it has been hypothesized that the CSF plays a crucial role in protecting the 15 
brain parenchyma against detrimental changes in the aged brain, in PD and in MS [20, 21]. In 16 
our experiments with the auditory system, multiple layers of donor cells were observed on the 17 
surface of the auditory nerve for as long as 3 months after transplantation (Fig. 3C and D in ref. 18 
#10). The survival of these cells is likely to have depended initially on CSF nutrients and later 19 
also on nutrients from new host blood vessels. Following intraparenchymal injection the 20 
majority of donor cells die [10], possibly through lack of immediate support from the CSF and 21 
then the blood supply. BDNF was highly expressed in our astrogliotic auditory nerve model 22 
[10] and it might aid survival of donor cells both inside the auditory nerve and outside in the 23 




disruption of existing blood vessels and facilitate more efficient vascularization of the donor 1 
cell mass.  2 
 3 
What is the optimum number of donor cells?  4 
In intraparenchymal injection, estimating the optimum number of donor cells for delivery is 5 
difficult. The death rate is often very high, surpassing 90% in some studies [18]. Uncontrollable 6 
growth of a graft within the brain could lead to devastating consequences such as brain 7 
herniation and death [22], so it is desirable to develop a method of delivery that matches the 8 
number of donor cells to the capacity of the host environment. Following surface delivery to 9 
the auditory nerve we observed donor cells apparently entering the tissue some 2 to 3 months 10 
after transplantation (Figs. 3F/G, 2 months post-transplantation; and 3E, 3 months post-11 
transplantation in ref. #10), suggesting that cell entry may continue over a long period. During 12 
development, the number of oligodendrocyte precursor cells (OPCs) is proportional to the 13 
supply of platelet-derived growth factor (PDGF), the main mitogen for OPC, and the final 14 
number of cells appears to be regulated primarily by PDGF levels [23]. If this principle applies 15 
to the migration of donor cells following surface transplantation, then the number of donor cells 16 
applied would be less critical as it might be functionally related to the host environment. Further 17 
studies are warranted to investigate potential interactions between donor cells and the host 18 
environment to enable long-lasting, regulated cell entry in surface transplantation.  19 
 20 
Mobilization of transplanted cells to the lesion 21 
Experimental evidence for signaling from damaged tissue to donor cells came from a study on 22 
a rat model of stroke, following transplantation with conditionally immortal human neural stem 23 
cell line (MHP36 cells) [24] similar to the N33 cells used in our study [10] (see Box 2). The 24 




in both sensorimotor function and gross motor asymmetry were observed at 6–12 weeks post-1 
grafting [24]. In addition to stroke, similar homing phenomena have been reported in various 2 
diseases including SCI and inflammatory diseases [25-27]. It seems then that donor cells 3 
transplanted on the surface of the CNS could potentially be mobilized to the lesion site once 4 
they crossed the pia mater and entered the CNS, although the specific mechanisms mobilizing 5 
transplanted cells to the damaged tissue remain to be clarified. 6 
 7 
Donor cells can enter the CNS from its surface 8 
CSF circulates into the parenchyma of the brain and spinal cord along perivascular spaces [28, 9 
29], and in some studies, intrathecally injected cells have been shown to follow the same route 10 
[30, 31]. In a mouse model of MS, adult neural stem cells injected into the subarachnoid space 11 
(SAS) entered into demyelinating areas of the CNS and promoted remyelination with functional 12 
recovery, indicating that donor cells can pass through the brain surface under inflammatory 13 
conditions [30]. Light and electron microscopic observations in a rat SCI experiment 14 
demonstrated that hippocampal neurospheres injected into the SAS attached to the pial surface 15 
at the lesion and subsequently invaded extensively into the spinal cord tissue through the pia 16 
mater, although the pia mater over the lesion showed no obvious open damage [31].  17 
 18 
Donor cells transplanted on the surface of the astrocyte scar tissue show a variety of 19 
migration modes 20 
The geometry and composition of astrogliosis, including the astrocyte scar, depends on how 21 
and where it is formed (Box 3). At the root exit or entry zones of motor and sensory nerves, 22 
reactive astrocytes extend long processes following the contours of the nerve roots (the 23 
astrocyte outgrowth) (Box 3). In our study, donor cells appeared to enter the nerve 24 




and within the astrocyte scar, a surprising variety of cell migration modes was observed, 1 
reminiscent of homotypic, glia- and neuron-guided behaviour of newborn neurons in the 2 
developing CNS [32] (Figure 2 A,B,C). Moreover, the cells were aligned in chains along 3 
elongated astrocyte scar processes expressing glial fibrillary acidic protein (GFAP), resembling 4 
the rostral migratory stream where neuroblasts migrate within a GFAP+, tube-like structure [33, 5 
34] (Figure 2D). Preservation of the structure of the astrocyte scar thus seemed to aid rather 6 
than to inhibit integration of donor cells. It seems then that intraparenchymal injection risks 7 
destruction of critical structural and chemical cues needed for axon regeneration following cell 8 
transplantation. Indeed, intraparenchymal injection of donor cells into the auditory nerve failed 9 
to restore nerve function (Figure 1). In this experiment, the nerve was treated with 10 
chondroitinase ABC (ChABC) both at the time of nerve injury and at cell transplantation, which 11 
might facilitate interactions between the donor cells and the gliotic auditory nerve [10]. In the 12 
astrocyte scar, ChABC aids regeneration by digesting glycosaminoglycan (GAG) chains of 13 
CSPGs (chondroitin sulfate proteoglycans) that interact with receptors on growing neurons that 14 
prevent axon regeneration [35-37]. With ChABC, axon elongation is facilitated by such a 15 
receptor-mediated mechanism when donor cells express the CSPG side chain receptors [38, 39]. 16 
It is not known if the N33 cells used in our auditory nerve experiments express the CSPG side 17 
chain receptors but ChABC works through multiple mechanisms and can modify the immuno-18 
inflammatory environment of the injured CNS to coax it to be pro-generative niche [40, 41]. 19 
Characteristics of CSPGs in the astrocyte scar in SCI are pro-regenerative or regeneration-20 
inhibitory [42, 43] and hence one future direction could be to enhance the former and to remove 21 
the latter using yet-unidentified pharmacological agents to enhance its efficacy.  22 
 23 




The anatomical relationships between astrocytes and Schwann cells and the basal lamina (BL) 1 
in the normal condition are maintained even in the astrocyte outgrowth [44-46] (Figure 3A-C) 2 
(Box 3). Intriguingly, ultrastructural analysis shows that the astrocyte outgrowth directly and 3 
extensively apposes with Schwann cells within common basal lamina tubes, providing a route 4 
for regeneration between the CNS and the PNS (peripheral nervous system) and decreasing the 5 
mutual repulsion that normally exists at this boundary [45] (Figure 3B). This “astrocyte 6 
outgrowth-Schwann cell complex”, or AO-SC complex, may be exploited for regeneration 7 
across the CNS-PNS boundary (Figure 3C). Under the administration of neurotrophins, 8 
blockade of the Nogo signaling pathway and application of ChABC to digest CSPG side chains 9 
allows regenerating sensory axons to pass the transitional zone (TZ, Box 3, Figure 3A) and 10 
reach the spinal cord [47]. It is unlikely that there is another route for regenerating sensory 11 
axons apart from the AO-SC complex within the common BL, as observed in motor neuron 12 
regeneration (see below).  13 
 14 
Surface transplantation applied to the astrocyte outgrowth-Schwann cell complex as a 15 
potential treatment in motor neuron diseases and peripheral neuropathies 16 
Given that the AO-SC complex provides a “bridge” between the CNS and peripheral targets 17 
(Figure 3C), we believe that motor neuron diseases and peripheral neuropathies, including ALS, 18 
spinal muscular atrophy (SMA), post-polio syndrome (PPS) and Guillain-Barré syndrome 19 
(GBS), could be candidates for surface transplantation. Donor cells must traverse the BL to 20 
access the astrocyte outgrowth within it (Figure 3C). In our study on the auditory nerve, donor 21 
cells often entered the nerve in a homotypic fashion, interacting with each other in clusters at 22 
limited entry points (Figure 2A) [10]. Entry points probably arise through breaks in the BL that 23 
formed during nerve compression and subsequent degeneration (Figure 3C) (Figure 3E in ref. 24 




the BL is traversed by numerous cell types including neural cells [48]. Conveniently, 1 
regenerating motor axons retrace their former pathways along the BL to form neuromuscular 2 
junctions (NMJ) on the same muscle fibers that they originally innervated [49]. One can 3 
speculate that appropriate motor neuron progenitors placed on the astrocyte outgrowth in the 4 
anterior nerve roots might extend regenerating axons along the AO-SC complex to form 5 
synapses with muscle fibers at the NMJ (Figure 3C). Motor neurons upregulate laminin 6 
receptors (integrins) in response to injury [50], so if donor cells with appropriate characteristics 7 
are selected, they might harness rich laminins within the BL for their axon growth (Box 3). In 8 
turn, the soma of transplanted cells on the surface of the astrocyte scar are expected to be 9 
innervated by increased projections from upper motor neurons as observed in SMA [51] (Figure 10 
3C).  11 
 12 
Reactive astrocytes for axon guidance in deeper CNS regions 13 
Astrocyte scar tissue in NDDs with deeper CNS lesions differs from that in our auditory nerve 14 
injury model, not least because it does not include the AO-SC complex. We believe that surface 15 
transplantation could be clinically relevant in these NDDs as well, although the specific nature 16 
of astrogliosis must be taken into account for each condition (see Box 4). In an experiment 17 
where human neural stem cells (hNSCs) were injected into the striatum of a 1-methyl-4-phenyl-18 
1,2,3,6-tetrahydropyridine (MPTP)-induced animal model of PD, local astrocytes were 19 
recruited to the lesion site where they formed a scaffold for chains of transplanted, migrating 20 
cells [52], similar to those observed in the auditory astrocyte scar model [10]. In human PD, 21 
astrogliosis is limited and a mature astrocyte scar usually does not develop [53] and hence 22 
reactive astrocytes may play key roles in donor cell migration as evidenced in the experiment 23 
cited above [52]. We believe that transplantation of donor cells to the surface of the insula could 24 




which with the subthalamic nucleus is one of the main targets for PD treatment, lies 10 mm 1 
(probably less in the aged) below the insular surface [54], which can be reached through the 2 
Sylvian fissure. One crucial factor that determines the applicability of surface transplantation 3 
is the ‘shallowness’ - i.e., how far the lesion exists from the surface of host nervous tissue. As 4 
evidenced in the auditory astrocyte scar model, the shallower the scaffolds guiding to the final 5 
target from the surface, the easier it is for donor cells to reach the target. It is possible that this 6 
principle extrapolates to diseases in which lower motor neurons are compromised, including 7 
ALS, SMA, PPS and GBS (see above). 8 
  An essential requisite for donor cells to reach their targets within the CNS is a pro-9 
regenerative, intraparenchymal path for migration. The hippocampus is one of the main 10 
potential targets for cell transplantation in AD. In one damaged hippocampus model, donor 11 
cells migrated away from the transplantation site and were distributed throughout the lesioned 12 
CA1 (Cornu ammonis 1) field, with some associated functional recovery [55], suggesting the 13 
existence of an appropriate intraparenchymal path for donor cell migration. This is supported 14 
by the observation that new progenitor cells generated in the subventricular zone (SVZ) 15 
following cortical injury migrated toward the lesion using reactive astrocytes as the scaffold 16 
[56]. In human AD, astrocyte scars such as those observed in SCI do not occur [57] and instead 17 
hypertrophic reactive astrocytes surround and wrap amyloid beta deposition (senile plaques) 18 
[58, 59]. Such sequestration of toxic aggregates from healthy parts of the brain may provide a 19 
favorable, pro-regenerative migration route [43]. Reactive astrocytes not only upregulate 20 
production of extracellular matrix (ECM) proteins and adhesion molecules, including growth-21 
promoting molecules, laminin, N-cadherin, NCAM (neural cell adhesion molecule) and 22 
ﬁbronectin [60-63] but also become a rich source of chemokines for axon elongation [64, 65]. 23 
Stromal cell-derived factor-1 (SDF-1, CXCL12) is expressed on reactive astrocytes and 24 




to lesioned areas [66, 67]. The surface of the hippocampal fissure (sulcus) would be a suitable 1 
site for testing cell delivery because it is very close to important anatomical structures in the 2 
hippocampus, including the dentate gyrus and CA1 and 3 (less than 1 mm, see Fig. 2A1 and B1 3 
in [68]). Whilst this idea is speculative, we believe that the potential benefits justify exploratory 4 
experiments.  5 
   6 
Concluding remarks and future perspectives 7 
In this Opinion, we argue that astrogliosis, including the astrocyte scar, far from being a barrier, 8 
provides an important structural and biochemical scaffold for cell transplantation and 9 
regeneration. Studies in the auditory nerve model have shown that the astrocyte scar, if not 10 
physically disrupted, can be harnessed by surface delivery of appropriate donor cells for 11 
functional integration into the host (see Outstanding Questions). We speculate that deep-seated 12 
reactive astrocytes might similarly be harnessed by donor cells to treat a number of NDDs and 13 
that the potential benefits justify exploratory experiments in appropriate animal models This 14 
should not only enhance our understanding of astrogliosis and the astrocyte scar but also propel, 15 
we hope, the progress of cell-based therapies toward more effective clinical translation for 16 
nervous system repair. 17 
 18 
Acknowledgments:  19 
We thank Professor Emeritus Juichi Ito and Professor Koichi Omori, Department of 20 
Otolaryngology, Head and Neck Surgery, Kyoto University Graduate School of Medicine for 21 
his support. This work was supported by grants to T. S. from the Japan Society for the 22 
Promotion of Science. 23 





In the auditory astrocyte scar model, mechanical injury was applied to the CNS portion of the 1 
auditory nerve (AuN) (large red arrow in Figure I) to induce astrocyte scar formation [10, 69-2 
74]. In this model, neurons in the cochlear nuclei within the brainstem died trans-neuronally 3 
following death of auditory spiral ganglion neurons (small red arrows) [69, 73]. To simulate 4 
chronic aspects of NDDs, we waited 5 weeks after compression to establish an astrocyte scar 5 
before cell transplantation [10]. By comparison, in adult murine spinal cord injury, astrocyte 6 
scars form after two weeks [42]. We assessed the impact of compression on the host auditory 7 
nerve and nearby cochlear nucleus after 1, 4 and 25 weeks by immunofluorescence, 8 
immunoblotting and mRNA analysis for GFAP (glial fibrillary acidic protein) and CSPG 9 
(Neurocan) [10]. GFAP expression continued with sustained accumulation of CSPG 10 
(Neurocan) after compression, but nestin expression was only transient, providing strong 11 
evidence for the formation of a mature astrocyte scar.   12 
 13 
Box 2: N33 cells 14 
The donor cells used in our auditory nerve injury study [10, 71], US/VOT-N33, are 15 
conditionally immortal cells derived from the ventral otocyst (the inner ear anlage) of an 16 
ED10.5 Immortomouse© embryo and selected for markers of auditory spiral ganglion neurons 17 
[75, 76]. These cells are clonal and their preparation is consistent between experiments with no 18 
requirement for time-consuming, expensive and complex conditioning. Cell variability is much 19 
less than that of pluripotent stem cells, in which phenotypic stability is not entirely predictable 20 
[24, 77-79]. The N33 cells proliferate at 33°C in the presence of γ-interferon but differentiate 21 
both in vitro and in vivo to express both structural and molecular markers of auditory spiral 22 
ganglion neurons at 37-39°C in the absence of γ-interferon [71, 75, 76]. Further studies with 23 
immature cells such as tissue-specific stem cells or progenitor cells are warranted because they 24 





Box 3: Transitional zone, basal lamina, Schwann cells and astrocyte outgrowth  2 
 3 
The transitional zone 4 
Spinal and cranial nerves normally project into peripheral nerves at an interface called the 5 
transitional zone (TZ) (Figure II (A), Figure 3A) [44]. In the CNS, myelin sheaths are formed 6 
by oligodendrocytes and the supporting tissue is astrocytic whereas in the peripheral tissue, 7 
axons are enwrapped by Schwann cells in the endoneurium, although axons project through the 8 
TZ. The TZ can be visualized with antibodies to GFAP because this intermediate filament 9 
protein is expressed only by astrocytes in the CNS (Figure II (A), Figure 3A).  10 
 11 
Basal lamina 12 
The basal lamina (BL) adjacent to the astrocytes on the surface of the CNS (the glia limitans) 13 
and the TZ region is continuous with that investing Schwann cells in the peripheral nerve [45] 14 
(Figure 3A). The BL is an electron-dense layer of extracellular matrix (ECM) containing a 15 
sheet-like basement membrane of collagen type IV that acts as a scaffold to integrate proteins 16 
such as laminin and ﬁbronectin [80]. For regeneration, the BLs provide a guide for cell 17 
migration and axon elongation [81] (Figure 3C).  18 
 19 
Schwann cells 20 
Following axon degeneration, Schwann cell columns (bands of Bungner) form within the basal 21 
lamina tubes that enclosed myelinating Schwann cells and their axons before nerve 22 
injury/degeneration. Schwann cell columns consist of myelin- and Remak-cell-derived repair 23 
Schwann cells in degenerated nerve [82, 83] (Figure 3B,C). Schwann cells rarely die after nerve 24 




regenerative molecules including glial cell-derived neurotrophic factor (GDNF), BDNF, 1 
neurotrophin-3 (NT-3), nerve growth factor (NGF) and cytokines that induce axon growth [83, 2 
85, 86]. In the auditory astrocyte scar model, a marked inward migration of cells transplanted 3 
on the surface of astrogliotic auditory nerve has been observed [10], implying that the astrocyte 4 
scar contains attractants such as BDNF, most likely from hair cells and Schwann cells (Box 1).  5 
 6 
The astrocyte outgrowth (the glial outgrowth) 7 
At the root exit and entry zones, the processes of reactive astrocytes follow the contours of the 8 
nerve roots (Figure II (B)). It has been repeatedly described in lower motor neuron diseases [87, 9 
88]. It was described for the first time as “glial bundles” in SMA [89], was later reported in 10 
ALS [90] and also linked to PPS in the anterior roots of a long-term polio survivor [91]. 11 
Ultrastructural studies revealed that the astrocyte outgrowth is composed of numerous 12 
astrocytic processes enclosed by the BL [90, 92] (Figure 3A,B).  13 
 14 
Box 4. Surface transplantation, caveats  15 
Cell transplantation involves complex interactions between donor cells, the host environment 16 
and changes in tissue pathology. Animal models cannot easily recreate human tissue pathology, 17 
especially those associated with longer periods of tissue degeneration and gliosis. This is further 18 
complicated by the wide range of potential donor cell types, cell delivery methods and 19 
assessments of functional recovery. Thus our ability to predict the outcome of cell 20 
transplantation experiments is difficult and both models and treatments for different conditions 21 
will almost certainly have to be closely tailored to each tissue and its pathology. The attraction 22 
of the auditory nerve model is that it allows relatively tight control of many of these variables 23 
(see Box 1) so that we can assess them in terms of functional recovery and more successfully 24 




whilst the model can indicate potentially important principles of cell transplantation there are 1 
important caveats to wider application to other forms of nerve injury and neurodegeneration. 2 
First, surface transplantation to the auditory nerve has not been tested in human patients and it 3 
is only through clinical trials that the true impact can be assessed. Second, the potential for 4 
donor cells to migrate greater distances to the target tissue is hard to predict and almost certainly 5 
dependent on the nature of tissue degeneration and on the selection of the donor cell type. This 6 
is particularly important for deeper lesions with more complex pathologies, including spinal 7 
cord injury. Third, the astrocytic response occurs whenever CNS neurons die but it differs 8 
between tissues and there can be progressive changes ranging from mild and reversible 9 
astrogliosis to the formation of more permanent astrocyte scars [43, 93-95]. Our auditory nerve 10 
model does not lead to the layered astrocytic scar formed with different cell-types [10] as 11 
observed in spinal cord injury [43]. Fourth, our auditory nerve model compared intra-neural 12 
injection with surface delivery in conjunction with application of Chondroitin ABC, the specific 13 
function of which requires further study. Despite these caveats, minimizing structural disruption 14 
to host tissue is a general principle that deserves further analysis in other pathologies and 15 
surface transplantation involves less invasive and possibly more measured entry of donor cells 16 
into host tissue. Note that it differs from the cell sheet technique, in which tissue lesions are 17 
covered with a layer of donor cells that do not individually penetrate the host [96]. 18 
 19 
 20 
Figure legends 21 
 22 
Figure 1. Surface transplantation vs. traditional intraparenchymal injection of donor cells 23 




Views of the right cerebellopontine angle after removal of the suboccipital bone. (A) Donor 1 
cells placed on the surface of an astrogliotic auditory nerve (thick curved arrows) autonomously 2 
migrate (thin curved arrows), differentiate and form synapses with hair cells (HC) and with 3 
neurons in the cochlear nucleus (CN) [10]. IAM, internal auditory meatus. (B) With traditional 4 
intraparenchymal injection (straight arrow), donor cells show apoptotic cell death with little 5 
sign of survival, migration and differentiation [10]. AuN, auditory nerve; Cr, retracted 6 
cerebellar hemisphere. 7 
 8 
Figure. 2. Donor cell behaviour observed in the auditory astrocyte scar model.   9 
(A) A chain of donor cells (arrows) entered an astrogliotic auditory nerve from its surface 10 
(dotted lines) with homotypic interactions. (B) Glia-guided migration of transplanted cells. A 11 
transplanted cell (arrow) intimately related to GFAP+ process (arrowheads) derived from the 12 
astrocyte scar. (C) Neuron-guided migration of transplanted cells. GFP+ Tuj1+ cell (arrow) 13 
attached to residual neurons (arrowheads). (D) Transplanted cells (arrows) formed chains 14 
within GFAP+ sheaths (arrowheads). Scale bars: 20 μm in A, B upper; 8 μm in B lower; 25 μm 15 
in C; 10 μm in D. (Reproduced from ref. #10 with permission). 16 
 17 
Figure 3. The transitional zone, the astrocyte scar and the astrocyte outgrowth - Schwann 18 
cell complex (A) The transitional zone is the interface between the central and peripheral 19 
portions of the nerve (see Box 3). The basal lamina (BL) investing Schwann cells is continuous 20 
with that of the glia limitans on the surface of astrocytes (see Box 3). (B) In neurodegeneration, 21 
the cellular strands of the repair Schwann cells (bands of Büngner) are formed (see Box 3 for 22 
detail). The strands are shown here in a simplified fashion but in fact they are markedly 23 
elongated, overlapped and often branched (see ref. # 82). Red dotted lines indicate possible 24 




 (C) Axons grow on pro-regenerative Schwann cell columns within laminin- and fibronectin-1 
rich basal lamina tubes. The thin arrow indicates the tip of a tube introduced to the target region 2 
to transplant donor cells endoscopically. Asterisks indicate discontinuities of the BL. A 3 
neuromuscular junction is shown to the right. The thick grey arrow at the top left of the image 4 
indicates possible plastic innervation from sprouts and/or upper neural tracts running on the 5 
astrocyte scar. MF, muscle fiber; NT, nerve terminal. 6 
 7 
Figure I. The method to induce the astrocyte scar in the auditory system. With compression 8 
injury applied to the CNS portion of the auditory nerve (AuN) (large red arrow), 9 
neurodegeneration proceeds both centrifugally and centripetally (small red arrows) with death 10 
of auditory spiral ganglion cells (SGC) and cochlear nucleus cells (CN), respectively. With CN 11 
cell death a prominent astrocyte outgrowth is induced (see Box 3). Auditory sensory hair cells 12 
produce BDNF/neurotrophin-3 (NT-3) and they do not degenerate. AuN, auditory nerve; fIAM, 13 
fundus of the internal auditory meatus (IAM); HC, hair cell; TZ, the transitional zone (see Box 14 
3) (modified from ref. #10 with permission). 15 
 16 
Figure II. Normal shape of the transitional zone and the astrocyte outgrowth following 17 
auditory nerve compression. (A) Normal shape of the transitional zone (down-pointing 18 
vertical arrows) of the auditory nerve (AuN). AuN-C, CNS portion of the auditory nerve; AuN-19 
P, PNS portion of the auditory nerve. Oblique arrows indicate auditory spiral ganglion cells. 20 
(B) Mechanical compression applied to the AuN-C (double arrows) induced the astrocyte 21 
outgrowth (arrow heads). Asterisks indicate some of astrocyte scar processes projecting into 22 
small bony canals beyond the fundus of the internal auditory canal. Note thinning of the 23 




auditory spiral ganglion cells after auditory nerve compression. Scale bars, 200 μm. Comp, 1 
compression. (modified from ref. #10 with permission)   2 
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  17 
Glossary  18 
 19 
Alzheimer’s disease (AD): A neurodegenerative disease and a leading cause of dementia. One 20 
of the pathophysiological signatures of the disease is deposition of amyloid plaques and 21 
neurofibrillary tangles, which are typically observed earlier (relative to other brain regions) in 22 





Amyotrophic lateral sclerosis (ALS): a neurodegenerative disease with progressive 1 
degeneration of the upper and lower motor neurons in the brain, brainstem and spinal cord that 2 
finally leads to paralyses in limb, bulbar and respiratory muscles.  3 
 4 
Guillain-Barré syndrome (GBS): a peripheral neuropathy that is occasionally life-threatening. 5 
Prominent axon loss is observed in the axonal form of the disease, which is more aggressive 6 
than the demyelinating form.  7 
 8 
Huntington’s disease (HD): an autosomal dominant neurodegenerative disorder characterized, 9 
among other symptoms, by involuntary ‘dancing’ movements and psychiatric symptoms 10 
progressing to dementia. Neuronal loss is marked in the striatum and vast areas of the brain are 11 
compromised. 12 
 13 
Multiple sclerosis (MS): the most frequent demyelinating disease of the CNS. It is 14 
characterized by demyelination, inflammation and axonal damage in the CNS due to unknown 15 
causes. At the demyelinated site, conduction impairment of nerve impulses occurs. The patients 16 
tend to repeat the remissions and aggravations of clinical manifestations. 17 
 18 
Parkinson’s disease (PD): a neurodegenerative disease caused mainly by degeneration of 19 
dopamine-containing neurons in the substantia nigra that project to the striatum (the caudate 20 
and putamen). Lewy bodies, an aggregation of α-synuclein, are observed in the lesions. Patients 21 
show slowness of movement, increased resistance to passive movements, shaking at rest, loss 22 





Post-polio syndrome (PPS): a serious condition with newly manifesting weakness, pain and 1 
apnea after acute infection of poliomyelitis caused by poliovirus. Lower motor neurons 2 
degenerate but the pyramidal tract is typically spared. PPS is an urgent problem because many 3 
of the estimated 20 million polio survivors worldwide develop PPS.  4 
 5 
Pyramidal tract: motor neural pathways are composed of two neurons, upper (UMNs) and 6 
lower motor neurons (LMNs). UMNs connecting the cerebral cortex and the brainstem or spinal 7 
cord form the pyramidal tracts (corticobulbar or corticospinal tract). LMNs connect the 8 
brainstem or spinal cord and effector organs such as skeletal muscles in the four extremities.  9 
 10 
Spinal muscular atrophy: a genetic disease in children caused by a defect in the survival 11 
motor neurons (SMN) gene. It involves extensive degeneration of lower motor neurons in the 12 
spinal cord and of brain stem motor nuclei with the pyramidal tract preserved. In the most severe 13 
type, patients show flaccid quadriplegia and die earlier. 14 
 15 
Temporal lobe epilepsy (TLE): a type of epilepsy that is often associated with pathologies in 16 
the hippocampal formation. In a substantial fraction of the patient population seizures are 17 
refractory to conventional antiepileptic drugs.  18 
1 
 
Outstanding questions  1 
 2 
Is intraparenchymal injection of donor cells the best way to ensure integration into the host 3 
neural circuitry with minimal damage to the host tissue? How does it compare with surface 4 
delivery? 5 
 6 
Can astrogliosis and the structure of astrocyte scar tissue be harnessed for more effective 7 
integration of donor cells? What structural and soluble cues are most important for donor cell 8 
survival and growth?  9 
 10 
In the absence of an immediate blood supply how can injected donor cells obtain nutrients 11 
from the host tissue to increase cell survival immediately after transplantation?  12 
 13 
What is the optimum number of donor cells for cell transplantation to ensure minimal damage 14 
to the host with maximal donor cell survival and integration? 15 
 16 
How can the growth of donor cells be facilitated either way across the boundaries between 17 
the central and peripheral nervous systems?   18 
 19 
What biochemical cues guide the migration and growth of endogenous or exogenous cells 20 
toward damaged nervous tissue? Do they recapitulate the modes of cell migration observed 21 
during development?  22 
 23 
How do the astrocytic response and the formation of the glial scar differ between different 24 
forms of nerve injury and neurodegenerative disorder?   25 
 26 
Do the selection of donor cells and the method of cell delivery have to be matched specifically 27 
to the host tissue and pathology? How can different cell transplantation strategies be 28 
compared objectively to assess outcomes? 29 
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